A phase3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination for 12 weeks in Subjcts with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Administered By

Awarded By

Contributors

Start/End

  • July 1, 2015 - June 30, 2017